Shelia Marie Violette

USPTO Granted Patents = 12 (Patent Applications = 11)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 4.6

ph-index = 4

Forward Citations = 86(Granted Patents)

Company Filing History:

University of California

patents

5. 1 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 2008-2024

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11879008 - Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator (2024-01-23),

2. 11053306 - Fusion protein constructs comprising anti-C3d antibody and factor H (2021-07-06),

3. 11053305 - Fusion protein constructs comprising anti-C3d antibody and CR1 polypeptide (2021-07-06),

4. 10035860 - Anti-alpha V beta 6 antibodies and uses thereof (2018-07-31),

5. 10035859 - Anti-alpha V beta 6 antibodies and uses thereof (2018-07-31),

6. 9745376 - [object Object] (2017-08-29),

7. 8992924 - [object Object] (2015-03-31),

8. RE44681 - Compositions and methods for inhibiting growth of SMAD4-deficient cancers (2013-12-30),

9. 8153126 - [object Object] (2012-04-10),

10. 7943742 - [object Object] (2011-05-17),

11. 7927590 - Compositions and methods for inhibiting growth of smad4-deficient cancers (2011-04-19),

12. 7465449 - [object Object] (2008-12-16),

Title: The Innovative Contributions of Shelia Marie Violette

Introduction

Shelia Marie Violette, an accomplished inventor based in Lexington, MA, has significantly contributed to the field of biomedical innovations. With a remarkable portfolio of 12 patents, her work primarily focuses on methods for treating complement-mediated diseases, showcasing her expertise and dedication to advancing medical science.

Latest Patents

Among her latest inventions, Violette has developed several innovative fusion protein constructs that can effectively bind to complement-associated antigens. One notable patent describes methods for treating complement-mediated diseases using fusion protein constructs that comprise an anti-C3d antibody and a complement modulator. These constructs are designed to incorporate a targeting moiety, which can be an antibody or an antigen-binding fragment, enhancing their efficacy in treating related conditions. Another pivotal patent highlights fusion protein constructs that feature both an anti-C3d antibody and a CR1 polypeptide, further illustrating her commitment to creating effective therapeutic solutions.

Career Highlights

Violette's professional journey includes significant positions at notable companies, such as Biogen Idec MA Inc. and Q32 Bio Inc. Her experiences in these leading biotechnology firms have propelled her innovations and provided her with a platform to make impactful advancements in the treatment of complex diseases.

Collaborations

Throughout her career, Violette has collaborated with esteemed colleagues, including Paul H. Weinreb and Kenneth J. Simon. These partnerships have fostered a collaborative environment, leading to groundbreaking research and the successful development of her patented technologies.

Conclusion

Shelia Marie Violette stands out as a pioneering inventor in the realm of biomedical innovation. Her twelve patents underscore her expertise and her dedication to improving human health through the development of novel therapeutic methods. As she continues to innovate, her contributions will undoubtedly leave a lasting impact on the treatment of complement-mediated diseases and beyond.

This text is generated by artificial intelligence and may not be accurate.